MK-4830

Generic Name
MK-4830
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
-
Unique Ingredient Identifier
-
Background

MK-4830 is a monoclonal antibody that targets the myeloid-specific immunoglobulin-like transcript (ILT) 4 receptor.

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)

First Posted Date
2022-07-07
Last Posted Date
2024-12-17
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
160
Registration Number
NCT05446870
Locations
🇨🇳

Changhua Christian Hospital-Obstetrics and Gynecology ( Site 1203), Changhua County, Changhua, Taiwan

🇪🇸

Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 1101), Barcelona, Spain

🇪🇸

Hospital Universitario 12 de Octubre-Medical Oncology ( Site 1104), Madrid, Madrid, Comunidad De, Spain

and more 42 locations

A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)

First Posted Date
2022-04-22
Last Posted Date
2024-12-02
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
120
Registration Number
NCT05342636
Locations
🇧🇷

ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO ( Site 2300), São Paulo, Sao Paulo, Brazil

🇫🇷

Hopital Claude Huriez - CHU de Lille ( Site 1100), Lille, Nord, France

🇫🇷

Centre Hospitalier Régional Universitaire de Brest - Hôpital Morvan ( Site 1104), Brest, Finistere, France

and more 43 locations

A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

First Posted Date
2022-04-08
Last Posted Date
2024-11-20
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
200
Registration Number
NCT05319730
Locations
🇨🇱

Clínica UC San Carlos de Apoquindo ( Site 4405), Santiago, Region M. De Santiago, Chile

🇮🇹

IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"-Oncologia Medica ( Site 32, Meldola, Emilia-Romagna, Italy

🇨🇳

Chang Gung Memorial Hospital at Kaohsiung ( Site 4003), Kaohsiung Niao Sung Dist, Kaohsiung, Taiwan

and more 49 locations

Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)

First Posted Date
2021-06-24
Last Posted Date
2024-12-03
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
110
Registration Number
NCT04938817
Locations
🇺🇸

Banner MD Anderson Cancer Center ( Site 0152), Gilbert, Arizona, United States

🇺🇸

Northside Hospital-Northside Hospital Oncology Network ( Site 0156), Atlanta, Georgia, United States

🇺🇸

Parkview Research Center at Parkview Regional Medical Center ( Site 0180), Fort Wayne, Indiana, United States

and more 44 locations

Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)

First Posted Date
2021-06-11
Last Posted Date
2024-11-19
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
120
Registration Number
NCT04924101
Locations
🇺🇸

UPMC Hillman Cancer Center ( Site 0127), Pittsburgh, Pennsylvania, United States

🇺🇸

MFSMC-HJWCI-Oncology Research ( Site 0128), Baltimore, Maryland, United States

🇺🇸

Cleveland Clinic-Taussig Cancer Center ( Site 0116), Cleveland, Ohio, United States

and more 46 locations

Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008)

First Posted Date
2021-05-20
Last Posted Date
2024-12-13
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
320
Registration Number
NCT04895722
Locations
🇺🇸

University of Chicago Medical Center-Medicine - Section of Hematology/Oncology - Gastrointestinal P, Chicago, Illinois, United States

🇺🇸

UPMC Hillman Cancer Center ( Site 1516), Pittsburgh, Pennsylvania, United States

🇨🇦

The Moncton Hospital-Oncology ( Site 0307), Moncton, New Brunswick, Canada

and more 106 locations

Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B)

First Posted Date
2020-11-12
Last Posted Date
2024-11-18
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
370
Registration Number
NCT04626518
Locations
🇺🇸

UTSW Medical Center ( Site 3003), Dallas, Texas, United States

🇺🇸

University of Chicago ( Site 3013), Chicago, Illinois, United States

🇺🇸

Yale-New Haven Hospital-Yale Cancer Center ( Site 3011), New Haven, Connecticut, United States

and more 48 locations

Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)

First Posted Date
2020-03-10
Last Posted Date
2024-11-19
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
90
Registration Number
NCT04303169
Locations
🇮🇹

Istituto Europeo di Oncologia ( Site 3301), Milano, Italy

🇮🇹

Policlinico Le Scotte - A.O. Senese ( Site 3377), Siena, Italy

🇺🇸

The Angeles Clinic and Research Institute ( Site 3009), Los Angeles, California, United States

and more 26 locations

KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

First Posted Date
2019-11-15
Last Posted Date
2024-11-26
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
450
Registration Number
NCT04165070
Locations
🇺🇸

Cleveland Clinic Main ( Site 0006), Cleveland, Ohio, United States

🇺🇸

The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C, Columbus, Ohio, United States

🇺🇸

Abramson Cancer Center of the University of Pennsylvania ( Site 0010), Philadelphia, Pennsylvania, United States

and more 36 locations

KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)

First Posted Date
2019-11-15
Last Posted Date
2024-12-12
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
135
Registration Number
NCT04165096
Locations
🇺🇸

Cleveland Clinic Main ( Site 0006), Cleveland, Ohio, United States

🇺🇸

Banner MD Anderson Cancer Center ( Site 0001), Gilbert, Arizona, United States

🇺🇸

City of Hope ( Site 0014), Duarte, California, United States

and more 36 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy